Stability testing contract also secured
[by Yu, Suin] ENCell announced on June 18 that it signed an agreement with CELLinCELLS, a Korean developer of advanced biopharmaceuticals, for the contract development and manufacturing (바카라사이트 벳위즈) of clinical trial drugs.
This agreement is distinct from the client's 바카라사이트 벳위즈 contract for clinical trial drugs and includes a separate stability testing contract. In accordance with the nondisclosure agreement between the two parties, key contractual details, including the deposit amount, will not be disclosed. CELLinCELLS is a regenerative therapy development company specializing in organoid technology, founded in 2014 by Professor Cho Jae-jin Cho of Seoul National University School of Dentistry.
ENCell holds the leading No. 1 position in sales and market share within the cell and gene therapy (CGT) 바카라사이트 벳위즈 sector in Korea, backed by an unmatched track record. The company offers optimal 바카라사이트 벳위즈 solutions to clients through a one-stop service and a globally certified GMP facility, uniquely equipped to produce both cells and viruses simultaneously, alongside a differentiated production and quality management system.
“Following the CDMO contract worth about KRW 2 billion (approximately USD 1.4 million) signed in May, we are currently in discussions with several companies to further expand the scale of CDMO contracts in the second half of this year, using this agreement with CELLinCELLS as a key momentum,” expressed Chang Jong-wook, CEO of ENCell. “Our efforts go beyond securing contracts, we place the highest priority on customer satisfaction and are making company-wide efforts to secure CDMO contracts for adeno-associated virus (AAV), which we have identified as a next-generation growth driver.”
“This contract is a highly encouraging outcome as we prepare for the Phase 2 clinical trial of ‘TRTP-101,’ our skin regeneration treatment candidate,” said Cho Jae-jin, CEO of CELLinCELLS. “If we are able to secure stable data, including efficacy, in the upcoming Phase 2 clinical trial, we are confident in our ability to present a new therapeutic paradigm for scar treatment and establish ourselves as a global leader in the ‘therapeutic organoid’ field,” he added.